Quick Answer
MEDIFAST INC reported Revenue From Contract With Customer Excluding Assessed Tax of $385.79 million for the year ending 2025.
- MEDIFAST INC showed a decrease of -36.0% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from MEDIFAST INC's annual report (Form 10-K), filed with the SEC on February 17, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2022: $417.60 million | Q2 2022: $453.33 million | Q3 2022: $390.40 million | Q1 2023: $348.98 million | Q2 2023: $296.19 million | Q3 2023: $235.87 million | Q1 2024: $174.74 million | Q2 2024: $168.56 million | Q3 2024: $140.16 million | Q1 2025: $115.73 million | Q2 2025: $105.56 million | Q3 2025: $89.41 million.
- Over the full 5 years of available data (2021 to 2025), MEDIFAST INC's Revenue From Contract With Customer Excluding Assessed Tax has declined by 74.7%.
- Historical annual values: Fiscal year 2025: $385.79 million | Fiscal year 2024: $602.46 million | Fiscal year 2023: $1.07 billion | Fiscal year 2022: $1.60 billion | Fiscal year 2021: $1.53 billion.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: